These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 12441314

  • 1. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
    Druker BJ.
    J Natl Cancer Inst; 2002 Nov 20; 94(22):1660-1. PubMed ID: 12441314
    [No Abstract] [Full Text] [Related]

  • 2. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS, Woo CW, Mackall CL, Thiele CJ.
    J Natl Cancer Inst; 2002 Nov 20; 94(22):1673-9. PubMed ID: 12441322
    [Abstract] [Full Text] [Related]

  • 3. Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.
    Tamborini E, Bonadiman L, Albertini V, Pierotti MA, Pilotti S.
    J Natl Cancer Inst; 2003 Jul 16; 95(14):1087-8; author reply 1088-9. PubMed ID: 12865456
    [No Abstract] [Full Text] [Related]

  • 4. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
    Gambacorti C.
    Tumori; 2001 Jul 16; 87(6):S10-2. PubMed ID: 11989608
    [No Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec 01; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
    O'Dwyer ME, Druker BJ.
    Lancet Oncol; 2000 Dec 01; 1():207-11. PubMed ID: 11905636
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
    Mauro MJ, O'Dwyer ME, Druker BJ.
    Cancer Chemother Pharmacol; 2001 Aug 01; 48 Suppl 1():S77-8. PubMed ID: 11587372
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    González I, Andreu EJ, Panizo A, Inogés S, Fontalba A, Fernández-Luna JL, Gaboli M, Sierrasesúmaga L, Martín-Algarra S, Pardo J, Prósper F, de Alava E.
    Clin Cancer Res; 2004 Jan 15; 10(2):751-61. PubMed ID: 14760098
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
    Sausville EA.
    J Natl Cancer Inst; 1999 Jan 20; 91(2):102-3. PubMed ID: 9923844
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ.
    Lancet; 2001 Dec 20; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract] [Full Text] [Related]

  • 18. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 20; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

  • 19. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
    Capdeville R, Buchdunger E, Zimmermann J, Matter A.
    Nat Rev Drug Discov; 2002 Jul 20; 1(7):493-502. PubMed ID: 12120256
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.